Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model

Cancer Immunology, Immunotherapy

Volumn 50, Issue 11, 2002, Pages 588-596

  Matar, P ^a   Rozados, V R ^a   Gervasoni, S I ^a   Scharovsky, O G ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Low dose cyclophosphamide; Lymphoma; Metastasis; Th2 Th1 switch

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE SWITCHING; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOMA; MALE; METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPLEEN CELL; TH1 CELL; TH2 CELL; TUMOR GROWTH;

EID: 0035674305     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0237-3     Document Type: Article

References (35)

1. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response
2. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden
3. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines
4. Augmentation of the human immune response by cyclophosphamide
5. Role of concomitant resistance in the development of murine lung metastases
6. The inbred IIM/Fm stock
7. Principles of cancer management: Chemotherapy
8. Interleukin 10 (IL-10. and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression
9. Immunomodulators: Immunosuppressive agents and immunostimulants
10. Genetic analysis of tumor resistance in an inbred line of rats
11. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells
12. How tumors escape immune destruction and what we can do about it
13. Biological properties of interleukin 10
14. Tumor-induced immune dysfunction
15. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice
16. The immunoaugmenting effects of cancer chemotherapeutic agents
17. Antimetastatic effect of a single low-dose of cyclophosphamide on rat lymphoma
18. Modulation of the antimetastatic effect of a single low dose of cyclophosphamide on rat lymphoma
19. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide
20. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response
21. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors
22. Th1 and Th2 cells: Differential patterns of lymphokine secretion lead to different functional properties
23. The role of IL-10 in cross regulation of Th1 and Th2 responses
24. The expanding universe of T-cell subsets: Th1, Th2 and more
25. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
26. An immunostimulation theory of tumor development
27. Immunostimulation of tumor growth
28. Stimulatory effects of immune reactions upon the growths of untransplanted tumors
29. Inmunomodulación por ciclofosfamida de la respuesta antitumoral a un sarcoma de rata
30. Cancer chemotherapeutics as immunomodulators
31. Immune-inflammatory mechanisms in IFN-α-mediated anti-tumor activity
32. Antitumor alkylating agents
33. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide
34. Inerleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules